A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer
Open-label, cohort study to determine the safety and tolerability of the combination of daily niraparib and daily brivanib for one 28-day cycle in patients with advanced ovarian cancer.
Ovarian Cancer
DRUG: niraparib|DRUG: Brivanib
Maximum tolerated dose, To determine the maximum tolerated dose of the combination of niraparib and brivanib for the treatment of patients with advanced ovarian cancer. The maximum tolerated dose (MTD) that is defined as the dose level at which less than one-third of patients will experience a dose-limiting toxicity (DLT)., 1 year
Assess the toxicity of the combination of niraparib and brivanib in each cohort by number of participants with treatment related adverse events, 1 year
Open-label, cohort study to determine the safety and tolerability of the combination of daily niraparib and daily brivanib for one 28-day cycle in patients with advanced ovarian cancer.